Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC.ALXN · Entity 137086 | SVP, Chief Compliance Officer | February 27, 2017 | March 01, 2017 |
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | General Counsel | February 21, 2025 | February 24, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALEXION PHARMACEUTICALS, INC.
Report date February 27, 2017 · Filed March 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 19,284 |
Ending reported balance
After 2017-02-28 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-02-27 · Sale · Disposed 260 · Balance 15,214 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Row 2 · 2017-02-28 · Sale · Disposed 330 · Balance 14,884 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Row 3 · 2017-02-28 · Grant · Acquired 4,400 · Balance 19,284 F3: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $131.25 · Expires 2027-02-28 | Direct | 8,700 |
Reported balance
After 2017-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-02-28 · Grant · Acquired 8,700 · Balance 8,700 F4: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.
F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F3: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date.
F4: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years.
Kalaris Therapeutics, Inc.
Report date February 21, 2025 · Filed February 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,517 |
Reported balance
After 2025-02-21 transaction · row 1
1 source rowRow 1 · 2025-02-21 · Sale · Disposed 106 · Balance 6,517 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 15,058 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15,058 F3: Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2025 Filed Feb 24, 2025 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 106 | $10.08 | $1,068.03 |
DisclosureSEC source: 0000950170-25-025630 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,517 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:16 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5 | $9.94 | $49.70 |
DisclosureSEC source: 0000950170-25-009205 · ownership.xml · nonDerivative · entry 2 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,623 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.81 to $10.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:16 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 47 | $9.45 | $444.33 |
DisclosureSEC source: 0000950170-25-009205 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,628 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.81 to $9.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 409 | $0.44 | $180.00 |
DisclosureSEC source: 0000950170-25-004834 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,541 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.462. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 11, 2024 Filed Dec 11, 2024 22:07 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GiftCommon Stock | 57,549 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-135443 · ownership.xml · nonDerivative · entry 2 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 346,348 F1 · kind: On December 11, 2024, the Reporting Person transferred 57,549 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 11, 2024 Filed Dec 11, 2024 22:07 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GiftCommon Stock | 57,549 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-135443 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,950 F1 · kind: On December 11, 2024, the Reporting Person transferred 57,549 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 432 | $0.55 | $236.95 |
DisclosureSEC source: 0000950170-24-129258 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,499 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 05, 2024 Filed Nov 6, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,272 | $0.86 | $1,965.05 |
DisclosureSEC source: 0000950170-24-122335 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,931 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.856 to $0.9151. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 22, 2024 Filed Oct 23, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 766 | $0.77 | $588.13 |
DisclosureSEC source: 0000950170-24-116644 · ownership.xml · nonDerivative · entry 2 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,203 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.76 to $0.7709. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 635 | $0.78 | $494.67 |
DisclosureSEC source: 0000950170-24-116644 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,969 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 377 | $0.81 | $307.18 |
DisclosureSEC source: 0000950170-24-112913 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,604 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 422 | $0.76 | $320.51 |
DisclosureSEC source: 0000950170-24-099106 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,981 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7373 to $0.7736. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,323 | $0.73 | $1,706.94 |
DisclosureSEC source: 0000950170-24-092808 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,403 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.73 to $0.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 20:25 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 757 | $0.74 | $559.57 |
DisclosureSEC source: 0000950170-24-085658 · ownership.xml · nonDerivative · entry 2 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,726 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7330 to $0.7534. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:25 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 634 | $0.75 | $475.56 |
DisclosureSEC source: 0000950170-24-085658 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,483 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7343 to $0.7925. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 20:14 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 379 | $0.72 | $272.88 |
DisclosureSEC source: 0000950170-24-081519 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,117 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:33 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 420 | $0.75 | $314.71 |
DisclosureSEC source: 0000950170-24-062977 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,496 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.74 to $0.7615. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,311 | $0.80 | $1,839.56 |
DisclosureSEC source: 0000950170-24-054509 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,916 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7801 to $0.8098. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 757 | $0.75 | $567.75 |
DisclosureSEC source: 0000950170-24-046907 · ownership.xml · nonDerivative · entry 2 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,227 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 626 | $0.75 | $469.88 |
DisclosureSEC source: 0000950170-24-046907 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,984 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7460 to $0.7562. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 368 | $0.77 | $284.10 |
DisclosureSEC source: 0000950170-24-041809 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,610 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7513 to $0.7801. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:16 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 385 | $0.70 | $267.65 |
DisclosureSEC source: 0000950170-24-018786 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,978 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6832 to $0.7150. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 21:40 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 8,869 | $0.67 | $5,942.23 |
DisclosureSEC source: 0000950170-24-011771 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,363 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.66 to $0.6914. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,302 | $0.67 | $873.38 |
DisclosureSEC source: 0000950170-24-007403 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,232 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6683 to $0.6797. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 424 | $0.64 | $270.94 |
DisclosureSEC source: 0000950170-24-002937 · ownership.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,534 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 162,500 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0001209191-23-006992 · doc4.xml · derivative · entry 3 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 497,844 Underlying: Common Stock · 162,500 shares Expires 2033-02-02 F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 87,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006992 · doc4.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,958 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 00:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 541 | $5.14 | $2,782.80 |
DisclosureSEC source: 0001209191-23-004501 · doc4.xml · nonDerivative · entry 4 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,458 F3 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.05 to $5.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 19, 2023 Filed Jan 24, 2023 00:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,032 | $5.08 | $10,317.89 |
DisclosureSEC source: 0001209191-23-004501 · doc4.xml · nonDerivative · entry 3 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,999 F3 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.94 to $5.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 02, 2022 Filed Jan 24, 2023 00:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GiftCommon Stock | 98,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004501 · doc4.xml · nonDerivative · entry 2 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 288,799 F1 · kind: On December 2, 2022, the Reporting Person transferred 98,346 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 02, 2022 Filed Jan 24, 2023 00:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GiftCommon Stock | 98,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004501 · doc4.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,031 F1 · kind: On December 2, 2022, the Reporting Person transferred 98,346 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:10 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,358 | $8.91 | $21,018.03 |
DisclosureSEC source: 0000899243-22-036018 · doc4.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 190,453 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 26, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.90 to $8.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 20, 2022 Filed Oct 26, 2022 20:15 UTC Amendment | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 553 | $9.36 | $5,176.47 |
DisclosureSEC source: 0000899243-22-034265 · doc4a.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,377 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 19, 2022 Filed Oct 24, 2022 22:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 553 | $9.36 | $5,176.47 |
DisclosureSEC source: 0000899243-22-034056 · doc4.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,377 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:02 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-029058 · doc4.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,930 F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 11:30 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0000899243-22-025235 · doc4.xml · derivative · entry 3 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2032-07-01 F4 · derivative.exercise_date: 25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 11:30 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-025235 · doc4.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,930 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. F2 · balance_after: Includes 3,623 shares acquired under the AlloVir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2022. Read SEC document |
| January 18, 2022 Filed Apr 4, 2022 20:23 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 56,744 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0000899243-22-013334 · doc4.xml · derivative · entry 3 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,744 Underlying: Common Stock · 56,744 shares Expires 2032-01-18 F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 18, 2022 Filed Apr 4, 2022 20:23 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 23,256 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013334 · doc4.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,307 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:35 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,200 | $39.14 | $86,107.56 |
DisclosureSEC source: 0001209191-21-017529 · doc4.xml · nonDerivative · entry 2 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 192,811 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.93 to $39.475. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:35 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,800 | $38.58 | $146,591.84 |
DisclosureSEC source: 0001209191-21-017529 · doc4.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 195,011 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.92 to $38.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $42.15 | $0.00 |
DisclosureSEC source: 0000899243-21-002759 · doc4.xml · derivative · entry 4 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2031-01-19 F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002759 · doc4.xml · nonDerivative · entry 3 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,051 F2 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| December 01, 2020 Filed Jan 22, 2021 00:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GiftCommon Stock | 41,514 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002759 · doc4.xml · nonDerivative · entry 2 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,811 F1 · shares: On December 1, 2020, the Reporting Person transferred 41,514 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: On December 1, 2020, the Reporting Person transferred 41,514 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 01, 2020 Filed Jan 22, 2021 00:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GiftCommon Stock | 41,514 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002759 · doc4.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,051 F1 · shares: On December 1, 2020, the Reporting Person transferred 41,514 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 03, 2020 Filed Aug 6, 2020 10:11 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | ConversionSeries B Convertible Preferred Stock · Derivative | 48,819 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-021599 · doc4.xml · derivative · entry 3 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 32,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F2 · ownership.nature: Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 03, 2020 Filed Aug 6, 2020 10:11 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | ConversionCommon Stock | 32,759 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-021599 · doc4.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 32,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F2 · ownership.nature: Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 22:42 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 200,600 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020926 · doc4.xml · derivative · entry 1 Miller Edward · CIK 0001619252 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,600 Underlying: Common Stock · 200,600 shares Expires 2030-07-29 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on July 29, 2021, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantOption to Purchase Common Stock · Derivative | 8,700 | $0.00 Strike: $131.25 | $0.00 |
DisclosureSEC source: 0000899866-17-000058 · wf-form4_148841553225370.xml · derivative · entry 4 Miller Edward · CIK 0001619252 · SVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,700 Underlying: Common Stock, par value $.0001 per share · 8,700 shares Expires 2027-02-28 F4 · shares: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-17-000058 · wf-form4_148841553225370.xml · nonDerivative · entry 3 Miller Edward · CIK 0001619252 · SVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,284 F3 · shares: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.